U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.
On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $29.18 which represents a decrease of $-0.02 or -0.07% from the prior close of $29.2. The stock opened at $29.21 and touched a low ...
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...